Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc.verified

FNCH

Price:

$11.95

Market Cap:

$19.19M

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis ...[Read more]

Industry

Biotechnology

IPO Date

2021-03-19

Stock Exchange

NASDAQ

Ticker

FNCH

The Enterprise Value as of November 2024 (TTM) for Finch Therapeutics Group, Inc. (FNCH) is 32.14M

According to Finch Therapeutics Group, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 32.14M. This represents a change of 161.73% compared to the average of 12.28M of the last 4 quarters.

Finch Therapeutics Group, Inc. (FNCH) Historical Enterprise Value (quarterly & annually)

How has FNCH Enterprise Value performed in the past?

The mean historical Enterprise Value of Finch Therapeutics Group, Inc. over the last ten years is 484.51M. The current 32.14M Enterprise Value has changed 563.41% with respect to the historical average. Over the past ten years (40 quarters), FNCH's Enterprise Value was at its highest in in the June 2021 quarter at 498.50M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

Quarterly (TTM)
Annual

Average

484.51M

Median

346.23M

Minimum

4.19M

Maximum

1.13B

Finch Therapeutics Group, Inc. (FNCH) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Finch Therapeutics Group, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 157.44%

Maximum Annual Enterprise Value = 1.13B

Minimum Annual Increase = -98.79%

Minimum Annual Enterprise Value = 4.19M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202310.79M157.44%
20224.19M-98.79%
2021346.23M-62.82%
2020931.22M-17.60%

Finch Therapeutics Group, Inc. (FNCH) Average Enterprise Value

How has FNCH Enterprise Value performed in the past?

The current Enterprise Value of Finch Therapeutics Group, Inc. (FNCH) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

120.41M

5-year avg

484.51M

10-year avg

484.51M

Finch Therapeutics Group, Inc. (FNCH) Enterprise Value vs. Peers

How is FNCH’s Enterprise Value compared to its peers?

Finch Therapeutics Group, Inc.’s Enterprise Value is greater than Werewolf Therapeutics, Inc. (139.97K), less than Edgewise Therapeutics, Inc. (3.19B), less than Decibel Therapeutics, Inc. (96.42M), less than Celcuity Inc. (634.84M), less than C4 Therapeutics, Inc. (462.75M), less than Ikena Oncology, Inc. (47.83M), less than Design Therapeutics, Inc. (258.23M), greater than Xilio Therapeutics, Inc. (-2975414.00), less than Eliem Therapeutics, Inc. (119.64M), less than Monte Rosa Therapeutics, Inc. (478.04M), less than Stoke Therapeutics, Inc. (501.96M), greater than Virax Biolabs Group Limited (5.49M), greater than Blue Water Vaccines, Inc. (8.67M), greater than Revelation Biosciences, Inc. (-8886223.00), greater than Hillstream BioPharma, Inc. (1.48M), greater than Kiora Pharmaceuticals, Inc. (4.42M), less than Nutriband Inc. (57.98M), greater than Quoin Pharmaceuticals, Ltd. (3.24M), greater than Longeveron Inc. (20.39M), greater than RenovoRx, Inc. (13.20M),

Build a custom stock screener for Finch Therapeutics Group, Inc. (FNCH) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Finch Therapeutics Group, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Finch Therapeutics Group, Inc. (FNCH) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Finch Therapeutics Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Finch Therapeutics Group, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Finch Therapeutics Group, Inc. (FNCH)?

What is the 3-year average Enterprise Value for Finch Therapeutics Group, Inc. (FNCH)?

What is the 5-year average Enterprise Value for Finch Therapeutics Group, Inc. (FNCH)?

How does the current Enterprise Value for Finch Therapeutics Group, Inc. (FNCH) compare to its historical average?